TNXP — Tonix Pharmaceuticals Holding Income Statement
0.000.00%
Last trade - 00:00- $122.56m
- $31.27m
- $10.09m
- 29
- 25
- 35
- 19
Annual income statement for Tonix Pharmaceuticals Holding, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 7.77 | 10.1 |
| Cost of Revenue | |||||
| Gross Profit | — | — | — | 3.03 | 2.33 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 50.5 | 92.3 | 112 | 126 | 147 |
| Operating Profit | -50.5 | -92.3 | -112 | -118 | -137 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -50.5 | -92.3 | -110 | -117 | -130 |
| Net Income After Taxes | -50.5 | -92.3 | -110 | -117 | -130 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -50.5 | -92.3 | -110 | -117 | -130 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -52.2 | -92.3 | -117 | -117 | -130 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -353,005 | -163,968 | -65,404 | -21,908 | -96.5 |